Table 1 Clinical characteristics of patients

Gender

1.852(0.517–6.638)

0.344

Male

133

25

108

Female

27

3

24

Age

0.181(0.065–0.505)

0.001

6.243(1.658–25.503)

0.007

≤ 60

77

5

72

>60

83

23

60

ECOG

1.022(0.353–2.961)

0.968

≤ 1

131

23

108

>2

29

5

24

Smoking index

0.271(0.114–0.645)

0.003

4.498(1.306–15.489)

0.017

<400

93

9

84

≥ 400

67

19

48

Respiratory comorbidity

1.500(0.573–3.929)

0.409

YES

31

7

24

NO

129

21

108

Tumor location

/

0.264

Upper left lobe

33

3

30

Lower left lobe

38

8

30

Upper right lobe

47

8

39

Lower right lobe (including middle lobe)

42

9

33

Pathological types

/

0.488

Adenocarcinoma

60

8

52

squamous cell carcinoma

46

9

37

Small cell carcinoma

52

10

42

large cell carcinoma

2

1

1

Stage (AJCC 8th)

/

0.215

I

10

3

7

II

18

4

14

III

132

21

111

IV

0

0

0

Mutation of gene

0.558(0.121–2.576)

0.455

YES

18

2

16

NO

142

26

116

Chemotherapy

0.222(0.094–0.527)

0.001

7.188(2.055–25.141)

0.002

YES

122

14

108

NO

38

14

24

Chemotherapy regimen

/

0.698

Paclitaxel + cisplatin/carboplatin

2

31

Pemetrexed + cisplatin/carboplatin

2

35

Etoposide + cisplatin/carboplatin

10

42

Immunotherapy

1.098(0.291–4.142)

0.890

Yes

16

3

13

NO

144

25

119

Targeted therapy

1.098(0.291–4.142)

0.890

Yes

16

3

13

NO

144

25

119

Postoperative Radiotherapy

1.149(0.393–3.362)

0.800

Yes

26

5

21

NO

134

23

111

Pulmonary ventilation function

/

0.744

Normal

42

9

33

Mild abnormality

30

4

26

Moderate abnormal

15

3

12

Severe abnormality

13

3

10

Extremely severe abnormality

3

0

3

Radiotherapy mode

5.697(0.736–44.078)

0.177

VMRT

136

27

109

SBRT

24

2

22

Dose fraction

/

0.247

60 Gy/28-30 F

114

21

93

45 Gy/30F

24

5

19

50 Gy/25F

7

1

6

40-60 Gy/8-10 F

7

1

6

45-54 Gy/18F

2

0

2

48-50 Gy/4-6 F

6

0

6